肝素钠与枸橼酸钠封管液在人工肝治疗肝衰竭患者的应用比较*

doi:10.3969/j.issn.1672-5069.2020.01.019

实用肝脏病杂志 ›› 2020, Vol. 23 ›› Issue (1): 66-69.doi: 10.3969/j.issn.1672-5069.2020.01.019

肝素钠与枸橼酸钠封管液在人工肝治疗肝衰竭患者的应用比较^*

马元吉, 许艳, 白浪, 陈芳, 唐红

610041 成都市四川大学华西医院感染性疾病中心

收稿日期:2018-11-05 出版日期:2020-01-10 发布日期:2020-01-14
通讯作者: 陈芳,E-mail:979566116@qq.com
作者简介:马元吉,男,37岁,博士研究生,主治医师。主要从事人工肝治疗肝衰竭相关研究。E-mail:maxe.doc@163.com
基金资助:
四川省卫生与计划生育委员会科研课题(编号：16PJ279)

Comparison of citrate to heparin as a catheter locking solution in patients with liver failure undergoing artificial liver support therapy

Ma Yuanji, Xu Yan, Bai Lang, et al

Center of Infectious Disease Study,West China Hospital,Sichuan University,Chengdu 610041,Sichuan Province,China

Received:2018-11-05 Online:2020-01-10 Published:2020-01-14

摘要/Abstract

摘要： 目的比较肝素钠与枸橼酸钠封管液在人工肝治疗肝衰竭患者中的有效性和安全性。方法 41例慢加急性乙型肝炎肝衰竭患者接受双重血浆分子吸附系统(DPMAS)序贯血浆置换(PE)治疗,在人工肝治疗后,分别采用肝素封管19例(79例次)和枸橼酸封管22例(80例次)。常规监测活化部分凝血活酶时间(APTT)。结果在封管后2 h,枸橼酸封管组APTT为(65.6±12.2)s,显著短于肝素封管组的【(89.8±43.1)s,P<0.01】;肝素封管组和枸橼酸封管组疑似导管相关性感染发生率分别为5.3%(1/19)和0.0%(0/22),两组差异无统计学意义(P=0.46);两组患者3 m生存率(52.3%对54.5%)、住院日、自发性细菌性腹膜炎、肝性脑病、肝肾综合征和消化道出血等主要并发症发生率差异无统计学意义(P>0.05)。结论在人工肝治疗后,应用4%枸橼酸钠封管有效,不会导致封管期间人体明显的凝血功能指标改变,可能更安全。

关键词: 肝衰竭, 双重血浆分子吸附系统, 血浆置换, 枸橼酸钠, 封管

Abstract: Objective To assess the safety and efficacy of citrate to heparin as a catheter locking solution in patients with liver failure undergoing artificial liver support system (ALSS) therapy. Methods 41 patients with acute-on-chronic liver failure were recruited in our hospital, and all the patients received double plasma molecular absorption system (DPMAS)and sequential plasma exchange (PE). The citrate or heparin was used as locking catheter solution in 22 patients with 80 times and in 19 patients with 79 times, respectively. Blood activated partial thromboplastin time (APTT) were monitored. Results Two hours after locking, the blood APTT in citrate-locking was (65.6±12.2)s, significantly shorter than【(89.8±43.1)s,P<0.01】 in heparin-locking; the incidences of catheter-related infection in the two groups was 0.0%(0/22) and 5.3%(1/19), respectively, without significant difference (P=0.46); there were no significant differences as respect to the 3-month survival (52.3% vs. 54.5%), hospital stay, spontaneous bacterial peritonitis, hepatic encephalopathy, hepatic-renal syndrome and gastrointestinal bleeding in the two groups (P>0.05). Conclusions The application of citrate for catheter locking has a good approach in patients with liver failure undergoing ALSS therapy, without obvious alteration of coagulation index, which might be safer.

Key words: Liver failure, Artificial liver support system therapy, Citrate, Lock solution

马元吉, 许艳, 白浪, 陈芳, 唐红. 肝素钠与枸橼酸钠封管液在人工肝治疗肝衰竭患者的应用比较^*[J]. 实用肝脏病杂志, 2020, 23(1): 66-69.

Ma Yuanji, Xu Yan, Bai Lang, et al. Comparison of citrate to heparin as a catheter locking solution in patients with liver failure undergoing artificial liver support therapy[J]. Journal of Practical Hepatology, 2020, 23(1): 66-69.

参考文献

[1] 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2012年版). 实用肝脏病杂志, 2013, 16(3): 210-216.
[2] Sarin SK, Choudhury A. Acute-on-chronic liver failure: terminology, mechanisms and management. Nat Rev Gastroenterol Hepatol, 2016, 13(3): 131-149.
[3] 李爽, 陈煜. 急性肝衰竭病情严重程度评估. 实用肝脏病杂志, 2017, 20(1): 17-20.
[4] 中国医院协会血液净化中心管理分会血液净化通路学组. 中国血液透析用血管通路专家共识(第1版). 中国血液净化, 2014, 13(8): 549-558.
[5] Polaschegg HD, Shah C. Overspill of catheter locking solution: safety and efficacy aspects. ASAIO J, 2003, 49(6): 713-715.
[6] Karaaslan H, Peyronnet P, Benevent D, et al. Risk of heparin lock-related bleeding when using indwelling venous catheter in haemodialysis. Nephrol Dial Transplant, 2001, 16(10): 2072-2074.
[7] Yevzlin AS, Sanchez RJ, Hiatt JG, et al. Concentrated heparin lock is associated with major bleeding complications after tunneled hemodialysis catheter placement. Semin Dial, 2007, 20(4): 351-354.
[8] James MF, Roche AM. Dose-response relationship between plasma ionized calcium concentration and thrombelastography. J Cardiothorac Vasc Anesth, 2004, 18(5): 581-586.
[9] 宁琪琪, 孟庆华, 朱跃科. 局部枸橼酸抗凝在肝衰竭患者进行持续肾脏替代治疗中的应用进展. 中华肝脏病杂志, 2018, 26(7): 549-552.
[10] Zhao Y, Li Z, Zhang L, et al. Citrate versus heparin lock for hemodialysis catheters: a systematic review and Meta-analysis of randomized controlled trials. Am J Kidney Dis, 2014, 63(3): 479-490.
[11] Liu J, Wang C, Zhao H, et al. Anticoagulant therapies versus heparin for the prevention of hemodialysis catheter-related complications: systematic review and Meta-analysis of prospective randomized controlled trials. Int J Clin Exp Med, 2015, 8(8): 11985-11995.
[12] Lok CE, Appleton D, Bhola C, et al. Trisodium citrate 4%--an alternative to heparin capping of haemodialysis catheters. Nephrol Dial Transplant, 2007, 22(2): 477-483.
[13] Bruyère R, Soudry-Faure A, Capellier G, et al. Comparison of heparin to citrate as a catheter locking solution for non-tunneled central venous hemodialysis catheters in patients requiring renal replacement therapy for acute renal failure (VERROU-REA study): study protocol for a randomized controlled trial. Trials, 2014, 15: 449.
[14] Abdel Azim ABE, ElSaid TW, El Said HW, et al. A randomized controlled clinical trial of 4% sodium citrate versus heparin as locking solution for temporary dialysis catheters among hemodialysis patients. Clin Nephrol, 2018, 90(5): 341-349.
[15] 赵宇亮, 杨济桥, 张凌, 等. 枸橼酸和肝素封管液预防血液透析长期留置导管相关感染的Meta分析. 中华肾脏病杂志, 2013, 29(8): 574-582.
[16] Khadzhynov D, Schelter C, Lieker I, et al. Incidence and outcome of metabolic disarrangements consistent with citrate accumulation in critically ill patients undergoing continuous venovenous hemodialysis with regional citrate anticoagulation. J Crit Care, 2014, 29(2): 265-271.
[17] Qin G, Shao JG, Wang B, et al. Artificial liver support system improves short- and long-term outcomes of patients with HBV-associated acute-on-chronic liver failure: a single-center experience. Medicine (Baltimore), 2014, 93(28): e338.
[18] Larsen FS, Schmidt LE, Bernsmeier C, et al. High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial. J Hepatol, 2016, 64(1): 69-78.
[19] Ma Y, Xu Y, Chen F, et al. Good tolerance of citrate accumulation due to plasma exchange among patients with acute-on-chronic liver failure: A prospective, observational study. Can J Gastroenterol Hepatol, 2018, 2018: 4909742.
[20] Polaschegg HD, Sodemann K. Risks related to catheter locking solutions containing concentrated citrate. Nephrol Dial Transplant, 2003, 18(12): 2688-2690.
[21] Power A, Duncan N, Singh SK, et al. Sodium citrate versus heparin catheter locks for cuffed central venous catheters: a single-center randomized controlled trial. Am J Kidney Dis, 2009, 53(6): 1034-1041.

肝素钠与枸橼酸钠封管液在人工肝治疗肝衰竭患者的应用比较^*

Comparison of citrate to heparin as a catheter locking solution in patients with liver failure undergoing artificial liver support therapy

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	范建高. 不忘初心,砥励前行[J]. 实用肝脏病杂志, 2020, 23(1): 1-1.
[2]	陈从新, 王莉苹. 应用皮质激素治疗肝衰竭存在什么争议？[J]. 实用肝脏病杂志, 2020, 23(1): 2-3.
[3]	范文瀚, 罗怡平, 李成忠. 糖皮质激素应用于肝衰竭治疗机制及其临床时机的把握[J]. 实用肝脏病杂志, 2020, 23(1): 7-9.
[4]	纪宇欣, 李树臣. 应用糖皮质激素治疗肝衰竭临床疗效研究进展[J]. 实用肝脏病杂志, 2020, 23(1): 10-13.
[5]	朱玉成, 闫家微, 孙景坤, 张秋月. 慢加急性肝衰竭患者血清二胺氧化酶水平及其临床意义探讨*[J]. 实用肝脏病杂志, 2019, 22(5): 672-675.
[6]	宋海燕, 陈曦, 张骏飞, 方雪晴, 董静, 陈照林, 潘劲劲, 刘波, 陈从新. 伏立康唑治疗肝衰竭并发肺部真菌感染患者疗效初步研究[J]. 实用肝脏病杂志, 2019, 22(5): 676-679.
[7]	张璇, 唐小云, 唐春银, 石学魁, 王惠琦, 张晓东, 沈海萍, 杨春辉. 中药方剂赤白汤对D-氨基半乳糖诱导的急性肝衰竭小鼠肠道菌群的影响研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 478-481.
[8]	王媛, 党盼玉, 王伟. 血浆置换联合连续性血浆透析滤过治疗慢加急性肝衰竭患者临床疗效及其对血浆细胞因子水平的影响[J]. 实用肝脏病杂志, 2019, 22(4): 541-544.
[9]	彭思璐, 刘冰, 孙宏, 林剑, 潘志颖, 邓存良. HBV相关慢加急性肝衰竭患者预后及其影响因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 545-548.
[10]	钟宋, 刘玉元, 刘树人, 周国柱, 刘崇文, 欧阳石. 慢性乙型肝炎患者肝组织自然杀伤细胞G2D表达水平的变化及其临床意义[J]. 实用肝脏病杂志, 2019, 22(3): 341-344.
[11]	潘劲劲, 董静, 宋海燕, 张俊飞, 陈照林, 刘波. 应用糖皮质激素治疗核苷（酸）类似物撤药性肝炎患者临床疗效评价[J]. 实用肝脏病杂志, 2019, 22(3): 357-360.
[12]	宋芳娇,朱冰,吕飒,田华,王海波,辛绍杰,游绍莉. 314例药物性肝衰竭患者临床特征分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 216-219.
[13]	高朋彬,赵晓彦,秦浩,吴凤影,钟海振,王琳,贾慧娜,李树娟. 戊型肝炎肝衰竭死亡原因分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 220-223.
[14]	张秀灵,段志文,杨瑞东,张晓敏,杨莉,杨海秋,李武. 血源紧张条件下血浆置换联合双重血浆分子吸附系统治疗早中期肝衰竭患者临床研究^*[J]. 实用肝脏病杂志, 2019, 22(2): 289-290.
[15]	范建高. 2018年《实用肝脏病杂志》精彩回顾[J]. 实用肝脏病杂志, 2019, 22(1): 1-3.